Rezafungin to prevent fungal infections in liver transplant patients
Part of Infections clinical trials.
This trial tests whether a medicine called rezafungin can help prevent serious fungal infections in people who have received a liver transplant. If you have certain risk factors, this study may offer extra protection against infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a liver transplant
- You are 18 years old or older
- You have at least one risk factor for fungal infection, such as a living donor transplant, a repeat transplant, a complex surgery, a specific type of bile duct connection, recent fungal infection, the need for kidney dialysis after transplant, or an additional surgery within 90 days of your transplant
- You do not have an active fungal infection at the time of transplant
- You are not allergic to echinocandin medicines
- You are not pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a targeted antifungal medicine (aimed at PTX3) can better prevent serious fungal infections in adults with AML or a related bone marrow disease who will have very low neutrophils. It may help lower the risk of dangerous infections during intensive chemotherapy hospital stays.
This trial is testing how the body processes the antifungal drug rezafungin in people who may have a fungal infection in their abdomen (peritonitis or intra-abdominal candidiasis). It aims to understand how the drug works and if it can help when other antibiotics haven't worked.
This trial tests how well rezafungin, an antifungal medicine, spreads in belly fluid when given during surgery for a suspected fungal infection in the abdomen. It aims to see if it's a good treatment option for patients needing abdominal surgery.
This Phase 2 trial tests rezafungin, an antifungal medicine, to treat Pneumocystis pneumonia (PCP) in adults living with HIV. It may help people recover faster or more effectively from this serious lung infection.
This trial tests BSG005, a new IV medicine for patients with invasive fungal infections that haven't improved with standard treatment or can't use standard treatments due to side effects or resistance. The goal is to see if it's safe and effective.
This trial tests a combination of antifungal medicines (liposomal amphotericin B and either isavuconazole or posaconazole) for people with blood cancers who develop a fungal infection despite taking preventive antifungal drugs. It aims to find a better treatment for these difficult infections.
Hear when a new Liver Transplant Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.